title: [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
authors.affiliation: Hypertoniezentrum München, Germany. info@hypertoniezentrum.de
authors.forename: M
authors.initials: M
authors.lastname: Middeke
mesh_terms: D000577:Amides / Q000009:adverse effects / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects* / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use; D001565:Benzoates / Q000009:adverse effects / Q000627:therapeutic use; D003329:Coronary Vasospasm / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D057239:Early Termination of Clinical Trials; D005650:Fumarates / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D017257:Ramipril / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology; D000077333:Telmisartan; D000092502:Renin Inhibitors
chemical_list: D000577:Amides; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D005650:Fumarates; D017257:Ramipril; D000077333:Telmisartan; D000092502:Renin Inhibitors; C446481:aliskiren